Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Los Angeles

Sacramento

New Haven

Washington D.C.

Boca Raton

Hollywood

Orlando

Tampa

Atlanta

Chicago

Boston

Ann Arbor

Detroit

Minneapolis

Cleveland

Hershey

Philadelphia

Pittsburgh

Nashville

Houston

Seattle

Edegem

Ghent

Kortrijk

Leuven

Mons

Roeselare

Edmonton

Hamilton

Greenfield Park

Olomouc

Ostrava

Prague

Ústí nad Labem

Grenoble

Lyon

Marseille

Paris

Pessac

Rennes

Berlin

Frankfurt

Freiburg im Breisgau

Lübeck

Budapest

Farkasgyepű

Szolnok

Tatabánya

Törökbálint

Milan

Orbassano

Parma

Gdansk

Mrozy

Warsaw

Wodzisław Śląski

A Coruña

Barcelona

Girona

Madrid

Seville